Do you think there will be an obesity sales force

Quote








I think we will have an obesity division.

Obesity drugs are not covered very well and take a lot of pull through work similar to Emgality.

We can’t have our DBU twos launching obesity & essentially still getting Mounjaro established. Plus the PC1 & 2 reps have their haves full just staying on top of their T2D targets.

PC3 is launching CKD so there’s absolutely no way they will launch CKD & obesity at the same time. Plus PC3 has a difficult time hitting their required metrics for the BI contract & the obesity drug would only take away from their metrics.

No other choice than to have an obesity division. They will have bigger territories similar to Novo.

Obesity will be a tough division. Bigger territory, very poor coverage and lots of PAs, working with call back nurses & PA person in office.
It will not launch anything like Mounjarou. Well unless Lilly makes a copay card where you can prescribe it for anything you want like they did Mounjaro
 




anonymous said:
I think we will have an obesity division.

Obesity drugs are not covered very well and take a lot of pull through work similar to Emgality.

We can’t have our DBU twos launching obesity & essentially still getting Mounjaro established. Plus the PC1 & 2 reps have their haves full just staying on top of their T2D targets.

PC3 is launching CKD so there’s absolutely no way they will launch CKD & obesity at the same time. Plus PC3 has a difficult time hitting their required metrics for the BI contract & the obesity drug would only take away from their metrics.

No other choice than to have an obesity division. They will have bigger territories similar to Novo.

Obesity will be a tough division. Bigger territory, very poor coverage and lots of PAs, working with call back nurses & PA person in office.
It will not launch anything like Mounjarou. Well unless Lilly makes a copay card where you can prescribe it for anything you want like they did Mounjaro
Click to expand...

no way PC3. This division needs to be reps who can work an account.. pull through and actually talk to providers, most Pc reps can’t, all they do is sample drop and try to schedule lunches. Weak group..many are lazy.
 




anonymous said:
no way PC3. This division needs to be reps who can work an account.. pull through and actually talk to providers, most Pc reps can’t, all they do is sample drop and try to schedule lunches. Weak group..many are lazy.
Click to expand...

PC3 is no different than PC1 & PC2.
Actually PC3 has to work PAs & pull through & total office selling with Emgality so PC3 has experience in that arena.

With that being said, I think obesity will have its own dedicated sales division
 




anonymous said:
no way PC3. This division needs to be reps who can work an account.. pull through and actually talk to providers, most Pc reps can’t, all they do is sample drop and try to schedule lunches. Weak group..many are lazy.
Click to expand...


Where are the reps going to come from?
You going to pull the 25 year old rep with 2.5 years of experience that went to a specialty rope he star no one else would apply for it because they didn’t want a huge territory for the same base as a PC rep?

Is that who is so qualified for an obesity role? Lol
 




anonymous said:
Where are the reps going to come from?
You going to pull the 25 year old rep with 2.5 years of experience that went to a specialty rope he star no one else would apply for it because they didn’t want a huge territory for the same base as a PC rep?

Is that who is so qualified for an obesity role? Lol
Click to expand...
Moron rep
 








I know… let’s get some of the oncology reps. They sit home most days of the week. They get paid good money already and are the brightest in lillly! Yeah… let’s get them!
 




there will def be an obesity force, mainly to stay ahead of FDA and DOJ problems promoting the two products which have a lot of gray area in between them. You would need to separate the two as much as possible along their indications and reps would need to stay in their lanes. Off-label issues are being looked at very closely these days.
 








Top Bottom
Back
Quote